Today, the EU Council and Parliament reached an agreement in principle on the long-awaited pharma reform package, but Europe's drug industry has already said it will not be enough to keep the sector ...

AstraZeneca and Daiichi Sankyo's TROP2-targeting drug Datroway has been approved by the European Commission for some previously untreated patients with metastatic triple-negative breast cancer (TNBC), ...

Two months after saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart. In final draft guidance (PDF), NICE ...

The patient access system isn't broken because people wanted it to fail. It's broken because it was built for an era where the phone and fax machine were the only universal interfaces, and business ...

IGNYTE showed that patients with confirmed progression on an anti-PD-1-based regimen who received RP1 plus nivolumab had a 34% response rate, with a median duration of 24.8 months, and 15% of them ...

According to a letter (PDF) signed by US Senators Elizabeth Warren (D-Mass), Angela Alsobrooks (D-Md), Richard Blumenthal ...

Artificial intelligence (AI) is becoming embedded into the fabric of quality, compliance, and production systems and shaping how teams interact with software, how processes are managed, and how work ...

A woman from the Wirral in the UK has become the first patient in the world to receive an experimental cancer vaccine ...

The once-daily, oral TEC/JAK3 inhibitor has shown efficacy in active and stable nonsegmental vitiligo (NSV) – the most common form of the disease – in which the most common form of vitiligo, ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another. The agreement with Gilead ...

Armed with positive results in two phase 3 trials, Takeda intends to file for approval of its oral psoriasis therapy zasocitinib in the US and other countries next year, with Bristol Myers Squibb's ...

CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder. Factor XIIa inhibitor ...